QuarterlyActivities Report and Appendix 4C Cash Flow Report
Filed with ASX · · 13 pages · English
Summary by 6ix AI
The report highlights a strong increase in EchoSolv AS usage, with notable growth in echocardiograms processed and the expansion of the sales team to support this growth. Additionally, the company has secured agreements with major health systems, including the Mayo Clinic and Mount Sinai, to enhance its market presence and facilitate product deployment. The report also emphasizes ongoing advancements in intellectual property and clinical validation efforts to support broader adoption of EchoSolv technologies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from EchoIQ
- EchoSolv AS deployed into Mount Sinai Health System
- Agreement with Mayo Clinic for EchoSolv HF
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- S&P DJI Announces March 2026 Quarterly Rebalance
- Appendix 4D 31 December 2025
Later from EchoIQ
- Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
- $762k R&D Tax Incentive Received
- Research collaboration secured with Mayo Clinic
- EchoIQ Strengthens Leadership Team and Clinical Advisory Network to Accelerate Next Phase of Commercial Growth and U.S. FDA Initiatives
- Binding HOA secured with Pro Medicus Limited
Follow EchoIQ into a list and get an email when it puts out news.
Follow EchoIQ